Trials / Terminated
TerminatedNCT00037622
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
Detailed description
Evaluation of safety and antiviral activity of the 5mg dose of ACH-126,443 for up to three months of treatment in the population described.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACH-126, 443 (beta-L-Fd4C) |
Timeline
- Completion
- 2003-05-01
- First posted
- 2002-05-20
- Last updated
- 2009-08-19
Source: ClinicalTrials.gov record NCT00037622. Inclusion in this directory is not an endorsement.